vs
Embecta Corp.（EMBC）与OFG BANCORP（OFG）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是OFG BANCORP的1.4倍（$261.2M vs $184.3M），OFG BANCORP净利率更高（30.3% vs 16.9%，领先13.4%），OFG BANCORP同比增速更快（0.9% vs -0.3%），OFG BANCORP自由现金流更多（$199.3M vs $16.6M），过去两年OFG BANCORP的营收复合增速更高（2.8% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
OFG Bancorp成立于1964年，总部位于波多黎各圣胡安，是东方银行的金融控股公司。公司通过东方银行、东方金融服务有限责任公司、东方保险有限责任公司等核心子公司，主要面向波多黎各和美属维尔京群岛市场，提供多元化的零售与商业银行、贷款、财富管理相关产品、服务及技术解决方案。
EMBC vs OFG — 直观对比
营收规模更大
EMBC
是对方的1.4倍
$184.3M
营收增速更快
OFG
高出1.2%
-0.3%
净利率更高
OFG
高出13.4%
16.9%
自由现金流更多
OFG
多$182.7M
$16.6M
两年增速更快
OFG
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $184.3M |
| 净利润 | $44.1M | $55.9M |
| 毛利率 | 61.9% | — |
| 营业利润率 | 31.9% | 25.7% |
| 净利率 | 16.9% | 30.3% |
| 营收同比 | -0.3% | 0.9% |
| 净利润同比 | — | 11.0% |
| 每股收益（稀释后） | $0.74 | $1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCOFG
| Q4 25 | $261.2M | $184.3M | ||
| Q3 25 | $264.0M | $186.2M | ||
| Q2 25 | $295.5M | $182.4M | ||
| Q1 25 | $259.0M | $178.6M | ||
| Q4 24 | $261.9M | $182.7M | ||
| Q3 24 | $286.1M | $174.7M | ||
| Q2 24 | $272.5M | $179.8M | ||
| Q1 24 | $287.2M | $174.4M |
净利润EMBCOFG
| Q4 25 | $44.1M | $55.9M | ||
| Q3 25 | $26.4M | $51.8M | ||
| Q2 25 | $45.5M | $51.8M | ||
| Q1 25 | $23.5M | $45.6M | ||
| Q4 24 | $0 | $50.3M | ||
| Q3 24 | $14.6M | $47.0M | ||
| Q2 24 | $14.7M | $51.1M | ||
| Q1 24 | $28.9M | $49.7M |
毛利率EMBCOFG
| Q4 25 | 61.9% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | 66.7% | — | ||
| Q1 25 | 63.4% | — | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 60.7% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 64.6% | — |
营业利润率EMBCOFG
| Q4 25 | 31.9% | 25.7% | ||
| Q3 25 | 21.4% | 33.0% | ||
| Q2 25 | 31.8% | 36.1% | ||
| Q1 25 | 24.3% | 33.3% | ||
| Q4 24 | 11.0% | 28.9% | ||
| Q3 24 | 9.2% | 35.4% | ||
| Q2 24 | 20.5% | 39.6% | ||
| Q1 24 | 13.6% | 38.9% |
净利率EMBCOFG
| Q4 25 | 16.9% | 30.3% | ||
| Q3 25 | 10.0% | 27.8% | ||
| Q2 25 | 15.4% | 28.4% | ||
| Q1 25 | 9.1% | 25.5% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | 5.1% | 26.9% | ||
| Q2 24 | 5.4% | 28.4% | ||
| Q1 24 | 10.1% | 28.5% |
每股收益（稀释后）EMBCOFG
| Q4 25 | $0.74 | $1.27 | ||
| Q3 25 | $0.44 | $1.16 | ||
| Q2 25 | $0.78 | $1.15 | ||
| Q1 25 | $0.40 | $1.00 | ||
| Q4 24 | $0.00 | $1.10 | ||
| Q3 24 | $0.24 | $1.00 | ||
| Q2 24 | $0.25 | $1.08 | ||
| Q1 24 | $0.50 | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $1.0B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $1.4B |
| 总资产 | $1.1B | $12.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCOFG
| Q4 25 | $201.3M | $1.0B | ||
| Q3 25 | $225.5M | $740.3M | ||
| Q2 25 | $230.6M | $851.8M | ||
| Q1 25 | $209.3M | $710.6M | ||
| Q4 24 | $210.0M | $591.1M | ||
| Q3 24 | $267.5M | $680.6M | ||
| Q2 24 | $275.1M | $740.4M | ||
| Q1 24 | $299.8M | $754.4M |
总债务EMBCOFG
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EMBCOFG
| Q4 25 | $-613.1M | $1.4B | ||
| Q3 25 | $-650.6M | $1.4B | ||
| Q2 25 | $-669.6M | $1.3B | ||
| Q1 25 | $-736.2M | $1.3B | ||
| Q4 24 | $-768.8M | $1.3B | ||
| Q3 24 | $-738.3M | $1.3B | ||
| Q2 24 | $-763.7M | $1.2B | ||
| Q1 24 | $-769.6M | $1.2B |
总资产EMBCOFG
| Q4 25 | $1.1B | $12.5B | ||
| Q3 25 | $1.1B | $12.2B | ||
| Q2 25 | $1.2B | $12.2B | ||
| Q1 25 | $1.1B | $11.7B | ||
| Q4 24 | $1.1B | $11.5B | ||
| Q3 24 | $1.3B | $11.5B | ||
| Q2 24 | $1.3B | $11.3B | ||
| Q1 24 | $1.2B | $11.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $217.7M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $199.3M |
| 自由现金流率自由现金流/营收 | 6.4% | 108.1% |
| 资本支出强度资本支出/营收 | 0.2% | 10.0% |
| 现金转化率经营现金流/净利润 | 0.39× | 3.90× |
| 过去12个月自由现金流最近4个季度 | $205.8M | $345.4M |
8季度趋势，按日历期对齐
经营现金流EMBCOFG
| Q4 25 | $17.2M | $217.7M | ||
| Q3 25 | $84.0M | $39.5M | ||
| Q2 25 | $81.2M | $35.9M | ||
| Q1 25 | $31.8M | $83.1M | ||
| Q4 24 | $-5.3M | $252.5M | ||
| Q3 24 | $26.6M | $58.1M | ||
| Q2 24 | $-2.1M | $95.1M | ||
| Q1 24 | $24.3M | $61.0M |
自由现金流EMBCOFG
| Q4 25 | $16.6M | $199.3M | ||
| Q3 25 | $76.7M | $35.5M | ||
| Q2 25 | $80.8M | $31.8M | ||
| Q1 25 | $31.7M | $78.7M | ||
| Q4 24 | $-6.8M | $231.2M | ||
| Q3 24 | — | $51.8M | ||
| Q2 24 | $-11.8M | $90.4M | ||
| Q1 24 | $20.9M | $54.8M |
自由现金流率EMBCOFG
| Q4 25 | 6.4% | 108.1% | ||
| Q3 25 | 29.1% | 19.1% | ||
| Q2 25 | 27.3% | 17.4% | ||
| Q1 25 | 12.2% | 44.1% | ||
| Q4 24 | -2.6% | 126.5% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | -4.3% | 50.3% | ||
| Q1 24 | 7.3% | 31.4% |
资本支出强度EMBCOFG
| Q4 25 | 0.2% | 10.0% | ||
| Q3 25 | 2.8% | 2.1% | ||
| Q2 25 | 0.1% | 2.3% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.6% | 11.7% | ||
| Q3 24 | 0.0% | 3.6% | ||
| Q2 24 | 3.6% | 2.6% | ||
| Q1 24 | 1.2% | 3.5% |
现金转化率EMBCOFG
| Q4 25 | 0.39× | 3.90× | ||
| Q3 25 | 3.18× | 0.76× | ||
| Q2 25 | 1.78× | 0.69× | ||
| Q1 25 | 1.35× | 1.82× | ||
| Q4 24 | — | 5.02× | ||
| Q3 24 | 1.82× | 1.24× | ||
| Q2 24 | -0.14× | 1.86× | ||
| Q1 24 | 0.84× | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
OFG
暂无分部数据
